Ischemic stroke, a leading cause of disability and mortality worldwide, is a complex cerebrovascular event with outcomes ...

Bayer today announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian. The study met its primary efficacy ...

A meta-analysis looked at people’s genetic profiles and found associations between blood type and risk of early-onset stroke.

Bayer said its new Phase III stroke study of asundexian hit both primary efficacy and safety goals. ・The update comes two ...

Initiation of anticoagulants is not linked to a reduced risk for ischemic stroke in older patients with atrial fibrillation, ...

Ischemic stroke is a complex cerebrovascular disorder characterized by highly unpredictable outcomes influenced by ...

Systematic review suggests GLP-1 receptor agonists offer strong preclinical neuroprotection in nondiabetic ischemic stroke, ...

Imperative Care, Inc. today announced the presentation of late-breaking, real-world data from a multi-center review of ischemic stroke patients treated with ADAPT 2.0, a next-generation approach to A ...

LDL cholesterol level < 40 vs ≥ 70 mg/dL is linked to lower rates of future major cardiovascular events in patients with ...

Leading Acute Ischemic Stroke companies are Acticor Biotech, DiaMedica Therapeutics, Lumosa Therapeutics, Bristol Myers ...

In a pair of randomized, observer-blinded clinical trials designed to evaluate optimal management of asymptomatic carotid ...